Exicure's Series D Round

Exicure raised a round of funding on October 23, 2015.

Exicure, formerly AuraSense Therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. The company's 3-dimensional, spherical nucleic acid (SNA) ar…

Articles about Exicure's Series D Round: